Dupilumab Improves Histopathologic Endpoints in Children With Eosinophilic Esophagitis: 52-Week Resu...
Dupilumab Improves Histopathologic Endpoints in Children With Eosinophilic Esophagitis: 52-Week Results From the Phase 3 EoE KIDS Trial
About this item
Full title
Author / Creator
Publisher
Northfield: College of American Pathologists
Journal title
Language
English
Formats
Publication information
Publisher
Northfield: College of American Pathologists
Subjects
More information
Scope and Contents
Contents
Results: At week 16, higher proportions of patients achieved counts1,6, and ,15 eosinophils per high-power field with dupilumab HE versus placebo. Rothenberg is a consultant with AstraZeneca, BMS, Celldex, ClostraBio, EnZen Therapeutics, GSK, Guidepoint, Pfizer, PulmOne, Regeneron Pharmaceuticals Inc, Sanofi, Santa Ana Bio, Serpin Pharma, Spoon Gur...
Alternative Titles
Full title
Dupilumab Improves Histopathologic Endpoints in Children With Eosinophilic Esophagitis: 52-Week Results From the Phase 3 EoE KIDS Trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3112177325
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3112177325
Other Identifiers
ISSN
0003-9985
E-ISSN
1543-2165
